NCT02885662View on ClinicalTrials.gov

Study of CS-3150 in Patients With Primary Aldosteronism

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 20, 2017

Study Completion Date

July 20, 2017

Conditions
Primary Aldosteronism
Interventions
DRUG

CS-3150

CS-3150 2.5 to 5.0 mg , orally.

Trial Locations (1)

222-0036

Japan Organaization of Occupational Health and Safety(JOHAS), Yokohama Rosai Hospital, Yokohama

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT02885662 - Study of CS-3150 in Patients With Primary Aldosteronism | Biotech Hunter | Biotech Hunter